Establishment Labs (ESTA) raised its 2026 revenue guidance and narrowed operating losses, signaling accelerating adoption of its Cellfina cellulite-treatment platform and body-contouring device portfolio. The guidance lift reflects both domestic U.S. traction and international expansion, particularly in markets where cellulite treatment commands premium pricing and high patient satisfaction.